Bessemer Group Inc. Has $18.14 Million Stock Holdings in Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH)

Bessemer Group Inc. increased its holdings in shares of Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH - Free Report) by 2.4% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 488,630 shares of the company's stock after acquiring an additional 11,609 shares during the quarter. Bessemer Group Inc. owned about 1.02% of Amphastar Pharmaceuticals worth $18,144,000 as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors have also bought and sold shares of the business. Raymond James Financial Inc. bought a new position in shares of Amphastar Pharmaceuticals during the fourth quarter worth approximately $3,450,000. Renaissance Group LLC grew its position in Amphastar Pharmaceuticals by 42.5% during the fourth quarter. Renaissance Group LLC now owns 99,572 shares of the company's stock worth $3,697,000 after buying an additional 29,696 shares in the last quarter. Renaissance Technologies LLC increased its stake in Amphastar Pharmaceuticals by 7.4% during the 4th quarter. Renaissance Technologies LLC now owns 525,500 shares of the company's stock worth $19,512,000 after acquiring an additional 36,100 shares during the period. Bank of Montreal Can raised its holdings in Amphastar Pharmaceuticals by 4.6% in the 4th quarter. Bank of Montreal Can now owns 8,215 shares of the company's stock valued at $305,000 after acquiring an additional 361 shares in the last quarter. Finally, Trek Financial LLC lifted its position in shares of Amphastar Pharmaceuticals by 15.4% during the 4th quarter. Trek Financial LLC now owns 7,638 shares of the company's stock valued at $284,000 after acquiring an additional 1,021 shares during the period. Institutional investors and hedge funds own 65.09% of the company's stock.

Remove Ads

Amphastar Pharmaceuticals Price Performance

Shares of AMPH traded down $0.92 during mid-day trading on Tuesday, reaching $23.50. The company had a trading volume of 779,873 shares, compared to its average volume of 617,866. The company has a market capitalization of $1.12 billion, a price-to-earnings ratio of 7.83, a P/E/G ratio of 2.19 and a beta of 0.79. The company has a debt-to-equity ratio of 0.82, a quick ratio of 2.61 and a current ratio of 3.43. The company's 50 day simple moving average is $28.51 and its 200 day simple moving average is $37.90. Amphastar Pharmaceuticals, Inc. has a 1-year low of $22.74 and a 1-year high of $53.96.

Wall Street Analyst Weigh In

AMPH has been the subject of a number of analyst reports. Piper Sandler dropped their price target on Amphastar Pharmaceuticals from $36.00 to $32.00 and set a "neutral" rating for the company in a research note on Friday, March 21st. Needham & Company LLC reaffirmed a "hold" rating on shares of Amphastar Pharmaceuticals in a report on Thursday, April 10th.

Insider Buying and Selling at Amphastar Pharmaceuticals

In other news, CFO William J. Peters sold 4,231 shares of the stock in a transaction on Tuesday, March 4th. The stock was sold at an average price of $27.54, for a total value of $116,521.74. Following the completion of the transaction, the chief financial officer now directly owns 97,363 shares in the company, valued at approximately $2,681,377.02. This represents a 4.16 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Company insiders own 27.10% of the company's stock.

Amphastar Pharmaceuticals Company Profile

Amphastar Pharmaceuticals, Inc, a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency.